Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(9):650-651; doi:10.1093/jnci/94.9.650
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Friedrich, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedrich, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 9, 650-651, May 1, 2002
© 2002 Oxford University Press

NEWS

Cardiotoxicity Concerns Prompt Data Review in Breast Cancer Trial

M. J. Friedrich

Researchers have temporarily halted the accrual of new patients into one of three arms of a large phase III study designed to examine the activity and safety of the biological agent trastuzumab (Herceptin®) in treating women with early-stage breast cancer.

Study leaders took this precaution in January after a small number of patients in one arm of the trial developed congestive heart failure within a one-week period. Investigators will continue to assess the data in the next few months to determine whether it is prudent to reopen this arm to patients. Meanwhile, the two other study arms remain open to enrollment.

Women . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
A. U. Buzdar, N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas, R. L. Theriault, L. Pusztai, M. C. Green, B. K. Arun, S. H. Giordano, et al.
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer
J. Clin. Oncol., June 1, 2005; 23(16): 3676 - 3685.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. W. Tolcher, C. H. Takimoto, and E. K. Rowinsky
The Multifunctional, Multi-Institutional, and Sometimes Even Global Phase I Study: A Better Life for Phase I Evaluations or Just "Living Large"?
J. Clin. Oncol., November 1, 2002; 20(21): 4276 - 4278.
[Full Text] [PDF]